Bortezomib Hospira

(bortezomib)

Uses, side effects, dosage information & price range

Pfizer Europe MA EEIG

About this medicine

Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

Bortezomib AccordComposition: bortezomibAccord Healthcare S.L.U.

Price on RequestView Details →

Bortezomib SunComposition: bortezomibSUN Pharmaceutical Industries (Europe) B.V.

Price on RequestView Details →

Bortezomib Fresenius KabiComposition: bortezomibFresenius Kabi Deutschland GmbH

Price on RequestView Details →

VelcadeComposition: bortezomibJanssen-Cilag International NV

Price on RequestView Details →

Key Information

Salt / Composition

bortezomib